0001493152-23-025150.txt : 20230720
0001493152-23-025150.hdr.sgml : 20230720
20230720194817
ACCESSION NUMBER: 0001493152-23-025150
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230718
FILED AS OF DATE: 20230720
DATE AS OF CHANGE: 20230720
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: BAUM MARK L
CENTRAL INDEX KEY: 0001274282
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35814
FILM NUMBER: 231100818
MAIL ADDRESS:
STREET 1: C/O IMPRIMIS PHARMACEUTICALS, INC
STREET 2: 12264 EL CAMINO REAL, SUITE 350
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: HARROW HEALTH, INC.
CENTRAL INDEX KEY: 0001360214
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 450567010
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 102 WOODMONT BLVD
STREET 2: SUITE 610
CITY: NASHVILLE
STATE: TN
ZIP: 37215
BUSINESS PHONE: 615.733.4731
MAIL ADDRESS:
STREET 1: 102 WOODMONT BLVD
STREET 2: SUITE 610
CITY: NASHVILLE
STATE: TN
ZIP: 37215
FORMER COMPANY:
FORMER CONFORMED NAME: Imprimis Pharmaceuticals, Inc.
DATE OF NAME CHANGE: 20120301
FORMER COMPANY:
FORMER CONFORMED NAME: TRANSDEL PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20070912
FORMER COMPANY:
FORMER CONFORMED NAME: Bywater Resources, Inc
DATE OF NAME CHANGE: 20060421
4
1
ownership.xml
X0508
4
2023-07-18
0
0001360214
HARROW HEALTH, INC.
HROW
0001274282
BAUM MARK L
C/O HARROW HEALTH, INC.
102 WOODMONT BLVD, SUITE 610
NASHVILLE
TN
37205
1
1
0
0
Chief Executive Officer
0
Common Stock
2023-07-18
4
M
0
762300
A
2309629
D
Common Stock
2023-07-18
4
F
0
299968
18.23
D
2009661
D
Performance Stock Unit
2023-07-18
4
M
0
762300
0
D
Common Stock
762300
0
D
The 762,300 shares of Harrow Health, Inc. ("Harrow") common stock listed in Table I as "Acquired" represent shares issued based on vesting of performance stock units ("PSUs") granted to Mr. Baum under Harrow's 2017 Stock Incentive and Awards Plan (the "Incentive Plan") on July 23, 2021. The PSUs were settled in full (on a one-for-one basis) on July 18, 2023, following attainment of total stockholder return targets ranging from 50% - 175 % following the date of the award. The 299,968 shares of Harrow common stock listed in Table I as "Disposed" were not sold by Mr. Baum in any transaction; rather, they were shares of Harrow common stock withheld by the Company for payroll tax purposes from the same aforementioned 762,300 shares pursuant to the terms of the Incentive Plan.
/s/ Mark L. Baum
2023-07-20